🇺🇸 FDA
Patent

US 7163678

Reovirus for the treatment of ral-mediated cellular proliferative disorders

granted A61KA61K35/765

Quick answer

US patent 7163678 (Reovirus for the treatment of ral-mediated cellular proliferative disorders) held by ONCOLYTICS BIOTECH INC. expires Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
ONCOLYTICS BIOTECH INC.
Grant date
Tue Jan 16 2007 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 11 2027 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
31
CPC classes
A61K, A61K35/765